Entera Bio(ENTX) - 2024 Q4 - Annual Results

Exhibit 99.1 JERUSALEM, March 28 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. "2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1- 34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balan ...